

CLINICAL STUDY OF COMBINATION THERAPY WITH DOXAZOSIN AND TOLTERODINE FOR PATIENTS WITH OVERACTIVE BLADDER AFTER TRANSURETHRAL RESECTION OF THE PROSTATE

Hypothesis / aims of study

To evaluate the efficacy of combination therapy with doxazosin and tolterodine for patients with overactive bladder (OAB) after transurethral resection of the prostate (TURP).

Study design, materials and methods

Totally 86 patients with OAB after TURP were randomly divided into doxazosin group (n=46) and combination group (n=40). The doxazosin group accepted doxazosin extended release (ER) tablet 4 mg once daily, the combination group accepted doxazosin and tolterodine ER tablet 4 mg once daily. The international prostate symptom score (IPSS), overactive bladder symptom score (OABSS), prostate volume, residual urine volume and adverse reactions were recorded.

Results

The values of IPSS and Qmax were significantly improved after treatment ($P<0.05$) in doxazosin group. The values of IPSS, storage IPSS, OABSS, 3rd score of OABSS and Qmax were also significantly improved after treatment ($P<0.05$). While the reduction of IPSS, storage IPSS, OABSS and 3rd score of OABSS in combination group was significantly greater than that in tamsulosin group ($P<0.05$).

Interpretation of results

It is effective and safe for patients with OAB after TURP to accept the combination therapy with doxazosin and tolterodine ER tablet.

Concluding message

It is effective and safe for patients with OAB after TURP to accept the combination therapy with doxazosin and tolterodine ER tablet.

References

1. Tolterodine tartrate combining Indomethacin suppository for prophylactic treatment of overactive Bladder after transurethral resection of prostate«Chinese Journal of Andrology» 2010-03

Disclosures

Funding: none **Clinical Trial:** Yes **Public Registry:** Yes **Registration Number:** rjcc,20105566789 **RCT:** Yes **Subjects:** HUMAN **Ethics Committee:** rjcc **Helsinki:** Yes **Informed Consent:** Yes